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Abstract
Introduction: Severe acute kidney injury (AKI) can be treated with either continuous renal replacement therapy
(CRRT) or intermittent renal replacement therapy (IRRT). Limited evidence from existing studies does not support
an outcome advantage of one modality versus the other, and most centers around the word use both modalities
according to patient needs. However, cost estimates involve multiple factors that may not be generalizable to
other sites, and, to date, only single-center cost studies have been performed. The aim of this study was to
estimate the cost difference between CRRT and IRRT in the intensive care unit (ICU).
Methods: We performed a post hoc analysis of a prospective observational study among 53 centers from 23
countries, from September 2000 to December 2001. We estimated costs based on staffing, as well as dialysate and
replacement fluid, anticoagulation and extracorporeal circuit.
Results: We found that the theoretic range of costs were from $3,629.80/day more with CRRT to $378.60/day more
with IRRT. The median difference in cost between CRRT and IRRT was $289.60 (IQR 830.8-116.8) per day (greater
with CRRT). Costs also varied greatly by region. Reducing replacement fluid volumes in CRRT to ≤ 25 ml/min
(approximately 25 ml/kg/hr) would result in $67.20/day (23.2%) mean savings.
Conclusions: Cost considerations with RRT are important and vary substantially among centers. We identified the
relative impact of four cost domains (nurse staffing, fluid, anticoagulation, and extracorporeal circuit) on overall cost
differences, and hospitals can look to these areas to reduce costs associated with RRT.
Introduction
Renal replacement therapy (RRT) is one of the most
common clinical procedures in the intensive care unit
(ICU). Approximately 4-5% of critically ill patients
require RRT during the ICU stay, a figure that is surpris-
ingly consistent across countries [1]. However, the way in
which RRT is provided varies greatly from one region to
the next and even within regions or cities [2]. RRT can
be classified into two major modalities: continuous RRT
(CRRT) and intermittent RRT (IRRT). Although each
modality has a different set of advantages and disadvan-
tages [3-5], many patients may, at one time or another,
be appropriate candidates for either therapy, especially
when they are hemodynamically stable [5]. Results from
randomized controlled trials and meta-analyses have
failed to demonstrate a survival difference between these
two modalities [6-12]. Thus, many authors have sought
to determine whether any differences in costs exist when
one modality is used instead of another [13,14].
Unfortunately, no multicenter study has been conducted
to examine costs. Thus, the existing evidence is limited
and poorly generalizable. Not surprisingly, costs are deter-
mined by labor (that is, provider staffing patterns) and
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zers); these components vary widely across centers. As
part of the B.E.S.T Kidney (Beginning and Ending Suppor-
tive Therapy for the Kidney) study, a multicenter, multina-
tional, prospective, epidemiologic study aimed at
understanding multiple aspects of RRT at an international
level [1,15-17], data were obtained regarding each of these
cost dimensions. Thus, as part of the larger study, which
included patients from 53 centers and 23 countries, we
sought to investigate the cost aspects of RRT practice
across different centers in different countries around the
world. Our aim was to determine the range and variation
of costs across various centers and to provide a clear pic-
ture of the overall determinants of cost. Although costs at
one center may bear little resemblance to those at another,
the overall range of possible costs provides a meaningful
metric whereby therapies can be compared.
Materials and methods
Subjects
This study was conducted at 53 centers in 23 countries,
from September 2000 to December 2001. The study
protocol was approved by the Investigational Review
Board of the University of Pittsburgh as well as by the
Ethics Committees or Investigational Review Boards of
each participating site. Because of the anonymous and
noninterventional nature of the study, Ethics Commit-
tees in most centers waived the need for informed con-
sent. Where Ethics Committees or Investigational
Review Boards required informed consent, we obtained
formal written consent.
All patients who were older than 12 years (including
seven patients younger than 18 years, because several
units treated older children in their ICUs) and were
admitted to one of the participating ICUs during the
observational period were considered. From this popula-
tion, we included only patients who were treated with
RRT other than for drug poisoning. Patients with any
dialysis treatment before admission to the ICU or
patients with end-stage renal failure receiving chronic
dialysis were excluded. For the current analysis, we con-
sidered all centers treating the patients described above
but our analysis unit was the center not the patient–we
included no patient-level data in this analysis.
Measures
Data collection
Data were collected by means of an electronically pre-
pared Excel-based data collection tool. This was made
available to participating centers with instructions. All
centers were asked to complete data entry and e-mail
the data to the central office. On arrival, all data were
screened in detail by a dedicated intensive care specialist
for any missing information or logical errors or
insufficient detail or any other queries. Any queries gen-
erated an immediate e-mail inquiry with planned resolu-
tion within 48 hours.
We divided the centers into six regions based on geo-
graphical area as follow: Northern Europe: Belgium,
Czech Republic, Germany, Netherlands, Norway, Swe-
den, Switzerland, United Kingdom, and Russia; Southern
Europe: Greece, Italy, Israel, Portugal, and Spain; North
America: Canada, and the United States; South America:
Brazil, and Uruguay; Asia: China, Indonesia, Japan, and
Singapore; and Australia.
Cost analysis
All costs were converted to US dollars based on pub-
lished exchange rates as of June 1, 2009.
Information on nursing assignments was available
from all sites. Nursing time was determined by calculat-
ing the cost of additional nursing staff assigned to per-
form RRT or from the cost of changing ICU nurse
staffing as a result of performing CRRT. Nursing cost
w a st h e nd e t e r m i n e df r o mn u r s i n gt i m ea n df r o mb e s t
available data from each center on hourly costs includ-
ing all benefits. Where data were not available from the
hospital itself, we used figures obtained from local nur-
sing agencies. When no other source of data was avail-
able we estimated costs using data from similar
institutions in the same region.
Dialysate and replacement fluid cost was calculated by
multiplying the actual amount of fluid used for the first
24 hours by the cost of each type of fluid, which varied
by each center and country. Because of the on-line dia-
lysate production for IRRT, we only considered the cost
of dialysate as coming from bicarbonate concentrate.
Costs of replacement fluid for CRRT were calculated
from each commercial supplier used by each institution.
Data on fluid use was available from all sites, however
the actual costs of each fluid was available from 50 sites.
We did not consider costs associated with high volume
hemofiltration, defined as replacement fluid rate more
than 100 ml/min, in our analysis.
Anticoagulant cost was derived by multiplying the
amount of anticoagulant used for the first 24 hours by
the cost of anticoagulant. In most cases we obtained
these costs directly from each site; when necessary we
obtained the costs by contacting the manufacturer.
Extracorporeal circuit costs were estimated from the
combined cost of the dialyzer and disposable blood lines
which were used in the CRRT and IRRT systems. Data
on dialyzer type was available from all sites, however the
actual costs of each membrane was only available from
24 sites.
Statistical Analysis
D u et ot h ed e s c r i p t i v en a t u r eo fo u rs t u d yw ed i dn o t
attempt to perform extensive statistical analysis. Cost
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anticoagulant costs, and extracorporeal circuit cost
between CRRT and IRRT were calculated. The total
range, the interquartile ranges (75% and 25%) and med-
ian values were calculated.
Results
Characteristic of organizational features
Organizational features of the 53 centers in 23 countries
participating in our study are summarized in Table 1.
Public hospitals composed the majority of sites, followed
by private and mixed facilities.U n i v e r s i t y - b a s e dh o s p i -
tals were the most common, except in Australia, where
large community hospitals predominated. Most partici-
pating centers contained between 500 and 999 beds.
General (medical/surgical) ICU was the predominant
type of ICU, and most of these contained between 10
and 19 ICU beds.
Physician and nursing practices
For IRRT in the ICU, we found that both intensivists
and nephrologists prescribed therapy. However, at insti-
tutions where only one discipline prescribed, intensivists
were responsible for prescribing more often than were
nephrologists in Northern Europe (38.5% versus 23.5%)
and in Asia (44.4% versus 22.2%), whereas nephrologists
were the predominant prescribers in Southern Europe
(33.3% versus 11.1%), North America (87.5% versus
12.5%), and South America.(100% versus none). For
CRRT, intensivists prescribed therapy more than did
nephrologists in Northern Europe (84.6% versus 7.7%),
Southern Europe (41.7% versus 8.3%), Asia (88.9% ver-
sus 0%), and Australia (100% versus 0%), whereas
nephrologists still played the major role in North Amer-
ica (62.5% versus 25%) and South America (80% versus
20%). In most regions, dialysis nurses cared for IRRT,
whereas ICU nurses delivered CRRT (see Table 2).
Table 1 Organizational features of RRT by regions
Northern Europe Southern Europe North America South America Asia Australia
1. Number of centers (%) 13 (24.5) 12 (22.6) 8 (15.1) 5 (9.4) 9 (17.0) 6 (11.3)
2. Number of countries (%) 9 (39.1) 5 (21.7) 2 (8.7) 2 (8.7) 4 (17.4) 1 (4.3)
3. Public or Private hospital
- Public (%) 11 (84.6) 10 (83.3) 5 (62.5) 2 (40.0) 6 (66.7) 5 (83.3)
- Private %) 1 (7.7) 2 (16.7) 2 (25.0) 2 (40.0) 2 (22.2) 1 (16.7)
- Combine (%) 1 (7.7) 0 1 (12.5) 1 (20.0) 1 (11.1) 0
4. Type of hospital
- University hospital (%) 10 (76.9) 6 (50) 8 (100) 2 (40.0) 7 (77.8) 2 (33.3)
- Large community (%) 3 (23.1) 3 (25) 0 2 (40.0) 2 (22.2) 4 (66.7)
- Small community (%) 0 3 (25) 0 1 (20.0) 0 0
5. Number of beds
- 499 2 (15.4) 4 (33.3) 0 2 (40.0) 1 (11.1) 4 (66.7)
- 1499 5 (38.5) 5 (41.7) 6 (75.0) 3 (60.0) 4 (44.4) 2 (33.3)
- More than 999 6 (46.2) 3 (25) 2 (25.0) 0 4 (44.4) 0
6. Number of ICU beds
- 9 2 (15.4) 4 (33.3) 0 0 4 (44.4) 0
- 29 6 (46.2) 8 (66.7) 0 0 4 (44.4) 5 (83.3)
- More than 19 5 (38.5) 0 8 (100) 8 (100) 1 (11.1) 1 (16.7)
7. Type of ICU
- General/mixed 11 (84.6) 9 (75) 7 (87.5) 5 (100) 6 (66.7) 6 (100)
- Surgical 1 (7.7) 0 1 (12.5) 0 1(11.1) 0
- Specialty (Cardiothoracic,
Bone marrow transplantation, etc.)
1 (7.7) 3 (25) 0 0 2 (22.2) 0
RRT, renal replacement therapy; ICU, intensive care unit.
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We obtained nursing-cost data from 44 centers. Nursing
costs were greater with IRRT in most regions ($25.70/
day in Northern Europe, $47.10/day in Southern Europe,
$38.60/day in North America, and $38.60/day in Asia
(see Figure 1). The exception was Southern America,
w h e r eC R R Ti sm u c hm o r ec o s t l yt h a nI R R T( $ 6 8 1 . 4 0 ) .
In Australia, we cannot compare nursing costs for
CRRT and IRRT because IRRT was not performed in
the ICU at any of our sites.
Dialysate and replacement fluid cost
Given that dialysate can be compounded online by dia-
lysis machines, fluid costs (available from 50 centers)
were significantly greater with CRRT. South America
was the region where the highest median difference of
fluid cost was observed. Of note, the median treatment
doses (combining dialysate and replacement fluid) for
CRRT in each region were as follow: Northern Europe:
25.3 ml/min, Southern Europe: 25 ml/min, North Amer-
ica: 27.3 ml/min, South America: 33 ml/min, Asia was
21.3 ml/min, and Australia: 26.9 ml/min (Figure 2).
Anticoagulant cost
Anticoagulant costs were obtained from 49 centers.
Heparin was the most commonly used anticoagulant for
RRT, and overall, no significant difference was found for
anticoagulant cost between IRRT and CRRT. The excep-
tion was Asia (specifically Japan), where anticoagulant
costs for CRRT are significantly greater than for IRRT
(see Figure 3).
Extracorporeal circuit cost
The cost of extracorporeal circuits came from the blood
lines and the dialyzers. Data, from 24 centers, show that
for most regions, the costs of dialyzers were much
greater than the costs of blood lines. Slightly different
extracorporeal circuit costs were found between modal-
ities. The region that demonstrated the most difference
was Asia, followed by North America (Figure 4).
Total cost
When we combined data from all regions, we found that
dialysate and replacement fluid costs, and extracorporeal
circuit costs, were generally greater for CRRT compared
Table 2 Treatment features of RRT by regions
Northern Europe Southern Europe North America South America Asia Australia
1. Who prescribes IRRT?
- Nephrologist (%) 3 (23.5) 3 (33.3) 7 (87.5) 5 (100) 2 (22.2) 3 (60)
- Intensivist (%) 5 (38.5) 1 (11.1) 1 (12.5) 0 4 (44.4) 2 (40)
- Both (%) 5 (38.5) 5 (55.6) 0 0 3 (33.3) 0
2. Who prescribes CRRT?
- Nephrologist (%) 1 (7.7) 1 (8.3) 5 (62.5) 4 (80) 0 0
- Intensivist (%) 11 (84.6) 5 (41.7) 2 (25) 1 (20) 8 (88.9) 6 (100)
- Both (%) 1 (7.7) 6 (50) 1 (12.5) 0 1 (11.1) 0
3. Who directs IRRT administration?
- Physician (%) 0 0 0 0 1 (11.1) 0
- Dialysis nurse (%) 10 (76.9) 6 (75) 7 (87.5) 4 (80) 3 (33.3) 4 (80)
- ICU nurse (%) 1 (7.7) 2 (25) 1 (12.5) 0 3 (33.3) 1 (20)
- Technician (%) 1 (7.7) 0 0 0 2 (22.2) 0
- Physician and nurse 1 (7.7) 0 0 1 (20) 0 0
4. Who directs CRRT administration
- Physician (%) 1 (7.7) 1 (9.1) 0 3 (60) 3 (33.3) 0
- Dialysis nurse (%) 2 (15.4) 2 (18.2) 4 (50) 1 (20) 0 0
- ICU nurse (%) 8 (61.5) 8 (72.7) 4 (50) 0 5 (55.6) 6 (100)
- Technician (%) 0 0 0 0 1 (11.1) 0
- Physician and nurse 2 (15.4) 0 0 1 (20) 0 0
5. Nurse-to-patient ratio for IRRT 1.3 1.1 1.5 1.1 1.3 1
6. Nurse-to-patient ratio for CRRT 1.2 1.7 1.4 1.2 1.4 0.8
RRT, renal replacement therapy; IRRT, intermittent renal replacement therapy; CRRT, continuous renal replacement therapy; ICU, intensive care unit.
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together (combined cost), we found that cost differences
between CRRT and IRRT ranged from $3629.80/day
more with CRRT to $378.60/day more with IRRT
(Figure 5). A major contributor to cost differences
between CRRT and IRRT was the cost of fluids. How-
ever, some of this cost reflected higher-volume CRRT
(>25 ml/min) used at some sites. With ultrafiltration
flow rates for CRRT of 25 ml/min (approximately
25 ml/kg/h), this could reduce fluid costs and combine
cost by ~43.3% and 19.5%, respectively. We estimated the
median cost difference between CRRT and IRRT across
all centers to be $289.60/day (IQR, 830.80 - 116.8) per
day (greater with CRRT). We calculated that reducing
-2000 -1500 -1000 -500 0 500 1000
All regions 
CRRT > IRRT IRRT > CRRT
Northern Europe
Southern Europe
North America
South America
Asia
Figure 1 Median difference and range of nursing costs by region. The error bars represent the absolute range between the maximum
nursing cost of CRRT and the minimum nursing cost of IRRT on the right, and between the maximum nursing cost of IRRT and minimum
nursing cost of CRRT on the left. The box represents the 1
st and 3
rd quartiles of the nursing-cost range. The thick solid line represents the
median difference in nursing costs for CRRT and IRRT across all centers in each region in which data were available.
-500 -400 -300 -200 -100 0 100 200 300 400 500
All regions 
CRRT > IRRT IRRT > CRRT
Northern Europe
Southern Europe
North America
South America
Asia
Figure 2 Median difference and range of dialysate and replacement-fluid costs by region. The error bars represent the absolute range
between the maximum fluid cost of CRRT and the minimum fluid cost of IRRT, and between the maximum fluid cost of IRRT and minimum
fluid cost of CRRT. The box represents the 1
st and 3
rd quartiles of the fluid-cost range. The thick solid line represents the median difference in
fluid costs for CRRT and IRRT across all centers in each region in which data were available.
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Figure 3 Median difference and range of anticoagulant costs by region. The error bars represent the absolute range between the
maximum anticoagulant cost of CRRT and the minimum anticoagulant cost of IRRT, and between the maximum anticoagulant cost of IRRT and
minimum anticoagulant cost of CRRT. The box represents the 1
st and 3
rd quartiles of the anticoagulant-cost range. The thick solid line represents
the median difference in anticoagulant costs for CRRT and IRRT across all centers in each region in which data were available.
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All regions 
CRRT > IRRT IRRT > CRRT
Northern Europe
Southern Europe
North America
South America
Asia
Figure 4 Median difference and range of extracorporeal circuit costs by region. The error bars represent the absolute range between the
maximum extracorporeal circuit cost of CRRT and the minimum extracorporeal circuit cost of IRRT, and between the maximum extracorporeal
circuit cost of IRRT and minimum extracorporeal circuit cost of CRRT. The box represents the 1
st and 3
rd quartiles of the extracorporeal circuit-
cost range. The thick solid line represents the median difference in extracorporeal circuit costs for CRRT and IRRT across all centers in each
region in which data were available.
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would result in $67.20/day mean savings (23.2%).
Discussion
This study is, to our knowledge, the first multicenter,
multinational study that estimated cost differences
between CRRT and IRRT in critically ill patients. We
examined cost differences across four different domains
and found significant variability in clinical practice.
These differences resulted in a wide range of potential
cost differences, ranging from greater costs with CRRT
to greater costs with IRRT. In most regions, fluid and
extracorporeal circuit costs were the largest contributors
to the greater cost of CRRT.
Physician and nursing practice varied significantly by
region. In North and South America, nephrologists were
primarily responsible for both CRRT and IRRT, although
intensivists in Northern Europe and Asia played a more
dominant role for both therapies. For CRRT, we found
that in Northern Europe, Southern Europe, Asia, and
Australia, primarily intensivists prescribed CRRT. Our
results are consistent with those of Ronco et al.[ 2 ] ,w h o
reported survey data from 345 participants who attended
two international meetings, and found that 35% of cen-
ters had only nephrologists, 18%, only intensivists, and
36% had both prescribing CRRT.
We found that the cost of CRRT was usually greater
than that of IRRT, but this was not always so. Results
from previous single- or two-center studies showed
wide variability in cost estimates. Manns et al. [18]
reviewed charts from two tertiary ICUs in Canada and
demonstrated that the cost of performing CRRT ranged
between Can $3,486/week and Can $5,117/week,
whereas the cost of performing IRRT was Can $1,342/
week. In the same year, Vitale et al.[ 1 9 ]r e p o r t e dt h e
data from a single center in Italy, and found that the
daily cost of CRRT was €276.70, whereas the daily cost
of 4 h of IRRT was €247.83. Finally, Rauf et al. [20] esti-
mated that mean adjusted costs through to hospital dis-
charge were $93,611 and $140,733 among IRRT-treated
and CRRT-treated patients, respectively. In our study,
we found a range of total cost differences between
CRRT and IRRT, which included these prior estimates
but also included scenarios in which no difference in
cost existed between the modalities, as well as scenarios
in which IRRT was actually more expensive compared
with CRRT.
Although our analysis included four separate cost
domains, we could not estimate secondary cost differ-
ences arising from differences in resource allocation as a
result of the different therapies. For example, CRRT
may limit patient mobility to a greater extent compared
-4000 -3000 -2000 -1000 0 1000
Total cost
Extracorporeal circuit 
cost
Anticoagulant cost
Dialysate and RF cost
Nursing cost
CRRT > IRRT IRRT > CRRT
Figure 5 Median difference and range of total cost by cost domain. The error bars represent the range between the maximum cost
of each domain for CRRT and the minimum cost for IRRT and the maximum cost of each domain for IRRT and minimum cost for CRRT.
The box represents the 1
st and 3
rd quartiles of the total cost range. The thick solid line represents the range difference between the
median cost differences for CRRT and IRRT. The thick white line represents the median difference of fluid costs when we limit
replacement-fluid rate to 25 ml/min.
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Page 7 of 10with IRRT. If this difference resulted in greater use of
physical therapists, additional secondary costs would be
associated with CRRT. Conversely, if the use of CRRT
were associated with improved renal recovery, as sug-
gested by some observational studies [21], the added
cost of continued renal support with IRRT would greatly
increase cost differences in favor of CRRT. Available
evidence from randomized trials has not demonstrated a
survival benefit for CRRT when compared with IRRT
[5,6,16-20]. Similarly, these trials have not found consis-
tent differences in the ICU or hospital length of stay
when one modality is used instead of the other. How-
ever, such head-to-head comparisons between IRRT and
CRRT do not reflect clinical practice in most of the
world where each modality is used to meet specific clin-
ical needs [6]. Therefore, the portion of the RRT treat-
ment that is considered to be discretionary between
CRRT and IRRT may be limited. Nevertheless, it is
important to note that cost differences between these
modalities are determined largely by factors that can be
modified.
For example, the cost of CRRT in our study was sig-
nificantly influenced by the cost of fluids and therefore
the rate of their use. When we limited effluent (replace-
ment fluid plus dialysis) flow rate to 25 ml/min (~25
ml/kg/h), we could reduce fluid costs by ~43.3%. Given
the results of the Acute Renal Failure Trials Network
(ATN) study and the Randomized Evaluation of Normal
versus Augmented Level (RENAL) Replacement Therapy
Study [6,7], which found no survival advantage by
increasing effluent flow rates to 35 and 40 ml/kg/h,
respectively, reducing fluid use by reducing effluent flow
rates to 25 ml/kg/h would seem prudent - provided that
this minimal dose can be ensured.
Surprisingly, nursing staffing was a significant cost
component of IRRT, as shown in Figure 5. This finding
reflects two underlying practices that were highly variable
across centers. First, some centers increased ICU nurse
staffing (decreased nursing ratios) when CRRT was pro-
vided. In these centers, labor costs were greater with
CRRT. By contrast, for centers providing 1:1 nursing for
all ICU patients or not changing staffing when providing
CRRT, labor costs can be greater only when IRRT
requires additional staff from the dialysis unit. Second,
g i v e nt h a tm o s tI C U s( a so p p o s e dt od i a l y s i su n i t s )d o
not group their patients on dialysis, the typical IRRT ses-
sion is delivered by a dedicated dialysis nurse. Thus,
labor costs will inevitably be greater for IRRT relative to
CRRT in centers where ICU nurse staffing does not
change when CRRT is provided and when IRRT is pro-
vided by a dedicated (single-patient) dialysis nurse.
Another source of costs differences between CRRT
and IRRT came from the use of anticoagulation. In
Japan, the cost of anticoagulation is an important part
of the total cost of RRT: nearly 50% of RRT patients
(42.03%) in Japan were treated with nafamostat mesy-
late, a synthetic serine protease inhibitor that inhibits
coagulation and fibrinolysis [22]. The cost of this drug is
significantly greater than that of conventional heparin.
Our study had several limitations. First, it was not
designed to estimate the fixed costs of RRT, such as the
dialysis machine cost. Neither did we attempt to deter-
mine differences in physician billing, which varied
depending on the health care system of each center and
country.
Second, although we report a median cost difference
between modalities among our centers, our primary goal
was not to determine average costs. Instead, we
intended to determine the range and variability of costs
and their determinants. We believe that such informa-
tion is more valuable to an individual practitioner or
hospital, because local costs will vary but are likely to
fall somewhere with the range we observed and are
likely to be influenced by the same factors that we
found in our study. Our median cost figure is undoubt-
edly a reflection of the composition of centers in our
study, which may have been skewed toward those with a
particular interest in AKI in the ICU. However, because
we included a highly heterogeneous group of centers,
the ranges of costs we report, as opposed to the point
estimates, are likely to be highly generalizable.
Third, we had incomplete data on actual costs for cer-
tain domains and used regional references to estimate
these costs. These regional references likely underesti-
mate the variability between centers, particularly in
some regions.
Finally, we accepted that a mixture of developed and
developing countries exists in some regions such as in
Asia. Furthermore, our categorization of countries by
region was somewhat arbitrary, and wide differences
may exist between practice patterns within each
region. However, when the primary analysis is repeated
after excluding the 44 patients from three centers in
countries with arguably very different healthcare deliv-
ery systems (14 patients from Russia, six patients from
China, and 24 patients from Indonesia), our results
were not materially changed. We also realize that we
may underestimate the cost of anticoagulation, because
we do not include the cost of monitoring of anticoagu-
lation such as ionized calcium, or aPTT/ACT. How-
ever, our intent was to provide an overall picture of
the range of cost differences between IRRT and CRRT,
rather than specifically to estimate costs in each
region. Thus, the cost landscape we were able to illus-
trate provides the first international glimpse into this
important area.
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Cost considerations with RRT are important and vary
substantially among centers. Major contributors to RRT
costs included nurse staffing, dialysate and replacement
fluid, anticoagulation, and extracorporeal circuit costs.
We found that the confidence intervals for cost differ-
ences between CRRT and IRRT were wide and crossed
zero. Therefore, single-center cost estimates will lack
generalizability. We identified the relative impact of four
cost domains on overall cost differences, and hospitals
can look to these areas to reduce costs associated
with RRT. Reducing effluent flow rates to 25 ml/min
(~25 ml/kg/h) has the capacity to reduce fluid costs and
combined costs by ~43.3%, and 19.5%, respectively.
Key messages
￿ Combined cost differences across four domains
(nursing staff, fluid, anticoagulation, and extracor-
poreal circuit cost) of CRRT are higher than those
of IRRT.
￿ Cost differences are highly variable across centers
and include scenarios in which either therapy is
more or less expensive compared with the other.
￿ Fluid and extracorporeal circuit costs are major
determinants of cost for CRRT, whereas human
resource costs (nursing) are the major determinant
of cost for IRRT.
￿ Limiting the rate of replacement fluid to 25 ml/
min, as per the current best evidence for dose of
CRRT, can reduce the fluid cost and combined cost
of CRRT and the median difference in cost between
CRRT and IRRT by ~43.3%, 19.5%, and 23.2%,
respectively.
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